开云app官网登录入口网页版-官方正版

#治疗失败#

86篇内容 | 1969人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1717322, encodeId=519d1e17322cb, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, objectType=article, longId=736106, objectId=5cc6e3610606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc6e3610606, replyNumber=0, likeNumber=71, createdTime=2023-01-17, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc6e3610606, moduleTitle=BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5cc6e3610606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717321, encodeId=09991e17321ef, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Melanoma Res：阿帕替尼联合替莫唑胺治疗免疫治疗失败后的晚期黑色素瘤患者的II期研究, objectType=article, longId=733988, objectId=09ebe339886f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09ebe339886f, replyNumber=0, likeNumber=131, createdTime=2022-09-22, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09ebe339886f, moduleTitle=Melanoma Res：阿帕替尼联合替莫唑胺治疗免疫治疗失败后的晚期黑色素瘤患者的II期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=09ebe339886f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717319, encodeId=36251e17319f0, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=肺癌EGFR基因突变治疗失败，应该如何处理？, objectType=article, longId=727993, objectId=d094e27993f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d094e27993f2, replyNumber=0, likeNumber=93, createdTime=2022-09-22, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d094e27993f2, moduleTitle=肺癌EGFR基因突变治疗失败，应该如何处理？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d094e27993f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717318, encodeId=0cc71e17318e3, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Infection: 化脓性肝脓肿患者治疗失败、复发和死亡的预测因素分析, objectType=article, longId=724427, objectId=63bbe2442797, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63bbe2442797, replyNumber=0, likeNumber=119, createdTime=2022-06-03, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63bbe2442797, moduleTitle=Infection: 化脓性肝脓肿患者治疗失败、复发和死亡的预测因素分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=63bbe2442797)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717317, encodeId=01db1e173179f, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, objectType=article, longId=724362, objectId=8304e2436281, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8304e2436281, replyNumber=0, likeNumber=70, createdTime=2022-06-03, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8304e2436281, moduleTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8304e2436281)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717314, encodeId=d28b1e17314cf, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效, objectType=article, longId=294426, objectId=f9a12944260c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9a12944260c, replyNumber=0, likeNumber=76, createdTime=2022-02-19, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9a12944260c, moduleTitle=Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f9a12944260c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717320, encodeId=717b1e173201a, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=75, createdTime=2022-09-05, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717313, encodeId=87461e1731315, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施, objectType=article, longId=293056, objectId=308a29305649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=308a29305649, replyNumber=0, likeNumber=72, createdTime=2022-01-06, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=308a29305649, moduleTitle=Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=308a29305649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717316, encodeId=33501e1731635, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, objectType=article, longId=295276, objectId=d9be2952e62d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be2952e62d, replyNumber=0, likeNumber=80, createdTime=2022-09-11, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be2952e62d, moduleTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d9be2952e62d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717312, encodeId=6f421e17312d7, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药, objectType=article, longId=221841, objectId=a33c221841fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a33c221841fa, replyNumber=0, likeNumber=67, createdTime=2022-04-21, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a33c221841fa, moduleTitle=凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a33c221841fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717310, encodeId=99c01e173102b, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Stroke：阿司匹林治疗失败的缺血性卒中患者抗血栓治疗可预防卒中, objectType=article, longId=219380, objectId=8dda219380cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dda219380cf, replyNumber=0, likeNumber=84, createdTime=2022-07-29, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dda219380cf, moduleTitle=Stroke：阿司匹林治疗失败的缺血性卒中患者抗血栓治疗可预防卒中, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8dda219380cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717315, encodeId=40271e17315d4, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, objectType=article, longId=295140, objectId=2fc82951409c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc82951409c, replyNumber=0, likeNumber=104, createdTime=2022-06-21, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc82951409c, moduleTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2fc82951409c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717309, encodeId=eff71e17309de, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Lung cancer：纳武利尤单抗用于既往治疗失败的NSCLC的真实世界研究, objectType=article, longId=217089, objectId=aa4a21e089bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa4a21e089bf, replyNumber=0, likeNumber=123, createdTime=2021-11-21, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa4a21e089bf, moduleTitle=Lung cancer：纳武利尤单抗用于既往治疗失败的NSCLC的真实世界研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa4a21e089bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717311, encodeId=e20a1e17311bb, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Stroke ：脑中风，阿司匹林治疗失败，有哪些抗血栓方案？, objectType=article, longId=219646, objectId=71dc2196463d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71dc2196463d, replyNumber=0, likeNumber=78, createdTime=2021-12-16, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71dc2196463d, moduleTitle=Stroke ：脑中风，阿司匹林治疗失败，有哪些抗血栓方案？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=71dc2196463d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717308, encodeId=33f51e17308fa, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=JCC: 维生素D与炎症性肠病患者体内α4β7+免疫表型相关并可以预测维多珠单抗治疗失败概率, objectType=article, longId=213519, objectId=787d2135194e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787d2135194e, replyNumber=0, likeNumber=79, createdTime=2021-11-28, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787d2135194e, moduleTitle=JCC: 维生素D与炎症性肠病患者体内α4β7+免疫表型相关并可以预测维多珠单抗治疗失败概率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=787d2135194e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717305, encodeId=3ce01e17305e7, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, objectType=article, longId=204234, objectId=b3d02042345e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d02042345e, replyNumber=0, likeNumber=90, createdTime=2021-08-22, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d02042345e, moduleTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b3d02042345e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717307, encodeId=7cb71e173075b, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Sci Rep：佩罗尼氏病患者胶原酶梭状芽孢杆菌治疗失败后的手术结果多中心临床研究 , objectType=article, longId=206469, objectId=261b2064692d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=261b2064692d, replyNumber=0, likeNumber=92, createdTime=2021-08-14, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=261b2064692d, moduleTitle=Sci Rep：佩罗尼氏病患者胶原酶梭状芽孢杆菌治疗失败后的手术结果多中心临床研究 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=261b2064692d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717304, encodeId=bffb1e1730490, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Lancet：塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者, objectType=article, longId=203388, objectId=15ae203388b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15ae203388b5, replyNumber=0, likeNumber=80, createdTime=2020-11-21, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15ae203388b5, moduleTitle=Lancet：塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=15ae203388b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717306, encodeId=c9a71e17306eb, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , objectType=article, longId=204687, objectId=679620468e97, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=679620468e97, replyNumber=0, likeNumber=95, createdTime=2021-09-25, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=679620468e97, moduleTitle=Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=679620468e97)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1717303, encodeId=98f31e17303dd, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, objectTitle=Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验, objectType=article, longId=202520, objectId=74bc20252090, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bc20252090, replyNumber=0, likeNumber=85, createdTime=2021-07-11, rootId=0, userName=ligang4450, userId=b1c332383811, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bc20252090, moduleTitle=Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74bc20252090)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

治疗失败

2020-05-29

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

BMC Med：用SGLT2抑制剂治疗的慢性肾病和2型糖尿病患者的心肾并发症和治疗失败的预测因素

2023-01-17

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Melanoma Res：阿帕替尼联合替莫唑胺治疗免疫治疗失败后的晚期黑色素瘤患者的II期研究

2022-09-22

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

肺癌EGFR基因突变治疗失败，应该如何处理？

2022-09-22

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Infection: 化脓性肝脓肿患者治疗失败、复发和死亡的预测因素分析

2022-06-03

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者

2022-06-03

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效

2022-02-19

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2022-09-05

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施

2022-01-06

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效

2022-09-11

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药

2022-04-21

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Stroke：阿司匹林治疗失败的缺血性卒中患者抗血栓治疗可预防卒中

2022-07-29

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？

2022-06-21

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Lung cancer：纳武利尤单抗用于既往治疗失败的NSCLC的真实世界研究

2021-11-21

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Stroke ：脑中风，阿司匹林治疗失败，有哪些抗血栓方案？

2021-12-16

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

JCC: 维生素D与炎症性肠病患者体内α4β7+免疫表型相关并可以预测维多珠单抗治疗失败概率

2021-11-28

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗

2021-08-22

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Sci Rep：佩罗尼氏病患者胶原酶梭状芽孢杆菌治疗失败后的手术结果多中心临床研究

2021-08-14

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Lancet：塞利尼索、硼替佐米和地塞米松联合用于一线治疗失败的多发性骨髓瘤患者

2020-11-21

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Eur Urol：锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应

2021-09-25

ligang4450 (审核中...)

前往app查看评论内容

#治疗失败#

Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验

2021-07-11

科室
- - 订阅+
  - 更多科室
工具
服务